(Tools, Reagents, and Techniques)
Our boilerplates and sample text for selected application sections may be used as a starting point for your applications, and should be modified to meet sponsor's requirements and to align with your proposed research plan.
This boilerplate addresses the NIH requirement for Sharing Research Resources. More>>
After the peer-reviewed publication of the unique research resource(s) [provide specific description / example(s)] generated from this project, the research tools/reagents/techniques (along with any necessary instructions or protocols) will be freely distributed to investigators at academic institutions for non-commercial research. If appropriate, the recipient investigators will provide written assurance and evidence that the research resources will not be further distributed by the recipient without consent of Rockefeller and will not be used for commercial purposes.
Requests from for-profit corporations to use the newly developed research tools/reagents/techniques commercially will be negotiated by our institution's technology transfer office. All licensing shall be subject to distribution pursuant to our institution's policies and procedures on royalty income. The technology transfer office will report any invention disclosure submitted to them to the appropriate Federal Agency. At the request of the funding agency, we will make the research resource available to any available Resource Centers.
Rockefeller University and the PI will adhere to the NIH Grants Policy on Sharing of Unique Research Resources including the "Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Grants and Contracts." Materials will be made available as soon as possible following publication, with terms driven by a Simple Letter Agreement for the transfer of materials or the Uniform Biological Material Transfer Agreement. This assures that research resources developed become readily available to the research community for further research, development, and application for the public benefit.
Should any intellectual property arise which requires a patent for commercial development to occur, the PI and OTT office will ensure that the technology remains widely available to the research community in accordance with NIH policies.
We value your comments and rely on your feedback to improve our services.
